<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284930</url>
  </required_header>
  <id_info>
    <org_study_id>15-1535</org_study_id>
    <nct_id>NCT04284930</nct_id>
  </id_info>
  <brief_title>Comparison of Local Anesthetic Infusion Pump Versus Depofoam Bupivacaine for Pain Management</brief_title>
  <official_title>Prospective, Randomized, Controlled Comparison of Local Anesthetic Infusion Pump Versus DepoFoam Bupivacaine For Pain Management After Unilateral Deep Inferior Epigastic Perforator Free Flap Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effective post surgical pain control in patients undergoing unilateral deep inferior&#xD;
      epigastric perforator (DIEP) free flap reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical to patient recovery, and can contribute to faster patient mobilization, shorter&#xD;
      hospital stays and reduced health care costs. The administration of local anesthetics via&#xD;
      wound infiltration is standard of care and an effective practice for post surgical pain&#xD;
      management, However this method only provides relatively brief analgesia, usually lasting&#xD;
      only 12 hours. Other FDA approved delivery systems using an indwelling fusion pump catheter&#xD;
      (On-Q pump) are currently being used in our practice and may be used to extend the duration&#xD;
      of action of locally administered analgesia by continuously infusing anesthetic into the&#xD;
      wound. Alternatively, a depot form of bupivacaine has been FDA approved and currently used to&#xD;
      deliver a single dose administered via wound infiltration for prolonged analgesia by allowing&#xD;
      for the diffusion of the drug over an extended period of time. Both of these products are&#xD;
      used as a standard practice during DIEP free flap reconstructions. However, no studies&#xD;
      compare the efficacy of these two methods patients undergong unilateral DIEP flap&#xD;
      reconstructions has been done in a prospective, randomized control manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Narcotic Usage</measure>
    <time_frame>total hospital stay, an average of 3 days</time_frame>
    <description>Post-op pain measured by total post-op Morphine equivalents</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Depobupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnQ Pump</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depobupivacaine</intervention_name>
    <description>surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.</description>
    <arm_group_label>Depobupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnQ pump</intervention_name>
    <description>group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.</description>
    <arm_group_label>OnQ Pump</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25% Bupivacaine</intervention_name>
    <description>group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.</description>
    <arm_group_label>bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non pregnant women&#xD;
&#xD;
          -  age 18 years or older&#xD;
&#xD;
          -  scheduled to have unilateral DIEP flap breast reconstruction.&#xD;
&#xD;
          -  Must have ASA physical status classification of 1,2, or 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concurrent or recent medical condition that could interfere with study participation&#xD;
&#xD;
          -  history of any of the following:&#xD;
&#xD;
          -  hepatitis&#xD;
&#xD;
          -  alcohol/substance abuse&#xD;
&#xD;
          -  uncontrolled psychiatric disorders&#xD;
&#xD;
          -  known allergy/ contraindication to any of the following:&#xD;
&#xD;
          -  amide-type local anesthetics&#xD;
&#xD;
          -  opioids&#xD;
&#xD;
          -  propofol&#xD;
&#xD;
          -  Body weight of less than 50 kg&#xD;
&#xD;
          -  have participated in another study involving an investigational medication with in the&#xD;
             past 30 days&#xD;
&#xD;
          -  taking analgesics, antidepressants, or glucocorticoids within the 3 days before&#xD;
             surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Risal Djohan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>December 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Risal Djohan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>local anesthetic continuous infusion pump</keyword>
  <keyword>local injection of Exparel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04284930/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was closed at interim analysis due to analyzed findings supporting use of exparel for pain control. We felt it would be unethical to continue to with overwhelming positive results.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Depobupivacaine</title>
          <description>Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.&#xD;
Depobupivacaine: surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.</description>
        </group>
        <group group_id="P2">
          <title>OnQ Pump</title>
          <description>Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.&#xD;
OnQ pump: group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.</description>
        </group>
        <group group_id="P3">
          <title>Bupivacaine</title>
          <description>Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.&#xD;
0.25% Bupivacaine: group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Depobupivacaine</title>
          <description>Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.&#xD;
Depobupivacaine: surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.</description>
        </group>
        <group group_id="B2">
          <title>OnQ Pump</title>
          <description>Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.&#xD;
OnQ pump: group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.</description>
        </group>
        <group group_id="B3">
          <title>Bupivacaine</title>
          <description>Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.&#xD;
0.25% Bupivacaine: group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="7.1"/>
                    <measurement group_id="B2" value="51.33" spread="6.25"/>
                    <measurement group_id="B3" value="50" spread="5.7"/>
                    <measurement group_id="B4" value="51.12" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Narcotic Usage</title>
        <description>Post-op pain measured by total post-op Morphine equivalents</description>
        <time_frame>total hospital stay, an average of 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Depobupivacaine</title>
            <description>Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.&#xD;
Depobupivacaine: surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.</description>
          </group>
          <group group_id="O2">
            <title>OnQ Pump</title>
            <description>Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.&#xD;
OnQ pump: group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine</title>
            <description>Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.&#xD;
0.25% Bupivacaine: group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Narcotic Usage</title>
          <description>Post-op pain measured by total post-op Morphine equivalents</description>
          <units>mg/kg/day morphine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.5"/>
                    <measurement group_id="O2" value=".13" spread=".1"/>
                    <measurement group_id="O3" value="0.18" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events are collected while the patients were in the hospital, which was an average of 3 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Depobupivacaine</title>
          <description>Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.&#xD;
Depobupivacaine: surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.</description>
        </group>
        <group group_id="E2">
          <title>OnQ Pump</title>
          <description>Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.&#xD;
OnQ pump: group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.</description>
        </group>
        <group group_id="E3">
          <title>Bupivacaine</title>
          <description>Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.&#xD;
0.25% Bupivacaine: group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Risal Djohan</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216 312-6146</phone>
      <email>djohanr@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

